0000899243-22-020055.txt : 20220527 0000899243-22-020055.hdr.sgml : 20220527 20220527212742 ACCESSION NUMBER: 0000899243-22-020055 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220525 FILED AS OF DATE: 20220527 DATE AS OF CHANGE: 20220527 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MCLAUGHLIN JOHN PETER CENTRAL INDEX KEY: 0001277967 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39473 FILM NUMBER: 22980140 MAIL ADDRESS: STREET 1: C/O PDL BIOPHARMA, INC. STREET 2: 932 SOUTHWOOD BOULEVARD CITY: INCLINE VILLAGE STATE: NV ZIP: 89451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LENSAR, Inc. CENTRAL INDEX KEY: 0001320350 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 320125724 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2800 DISCOVERY DRIVE STREET 2: SUITE 100 CITY: ORLANDO STATE: FL ZIP: 32826 BUSINESS PHONE: 888-536-7271 MAIL ADDRESS: STREET 1: 2800 DISCOVERY DRIVE STREET 2: SUITE 100 CITY: ORLANDO STATE: FL ZIP: 32826 FORMER COMPANY: FORMER CONFORMED NAME: LensAR Inc DATE OF NAME CHANGE: 20070703 FORMER COMPANY: FORMER CONFORMED NAME: LaserSoft Vision Inc DATE OF NAME CHANGE: 20050310 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-05-25 0 0001320350 LENSAR, Inc. LNSR 0001277967 MCLAUGHLIN JOHN PETER C/O LENSAR, INC. 2800 DISCOVERY DRIVE ORLANDO FL 32826 1 0 0 0 Common Stock 2022-05-25 4 A 0 4285 0.00 A 44343 D Stock Option (Right to Buy) 7.00 2022-05-25 4 A 0 15616 0.00 A 2032-05-25 Common Stock 15616 15616 D Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on May 25, 2023, subject to the Reporting Person's continued service to the Issuer through the vesting date. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer Includes 40,058 shares of the Issuer's common stock received by the Reporting Person in connection with the October 1, 2020 spin-off (the "Spin-Off Date") of the Issuer from PDL BioPharma, Inc. ("PDL") on account of his ownership of shares of PDL common stock. The option vests in twelve (12) substantially equal monthly installments commencing June 25, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. The option was granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. /s/ Thomas R. Staab, II, attorney-in-fact 2022-05-27